SYDNEY, April 15 (Reuters) - Shares of China's Duality Biotherapeutics 9606.HK were set to rise 91.3% in their Hong Kong debut on Tuesday after the company raised $213 million in an initial public offering launched as financial markets reacted savagely to the U.S tariffs package.
(Reporting by Scott Murdoch in Sydney and Donny Kwok in Hong Kong; Editing by Tom Hogue)
((Scott.Murdoch@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。